Maspin Expression in Cancer Biology

Maspin (mammary serine protease inhibitor) is a non-inhibitory member of the serine protease inhibitor superfamily that functions as a multifaceted tumour suppressor in a wide range of epithelia. Its expression is typically high in normal epithelial tissues but is frequently downregulated or mislocalised in malignancies. The pattern of maspin expression not only varies between tumour types but also within subcellular compartments, with nuclear maspin generally correlating with more favourable outcomes, whereas cytoplasmic or stromal localisation often aligns with tumour progression. Mechanistically, maspin has been implicated in the regulation of cell adhesion, apoptosis, differentiation and motility, acting through modulation of histone deacetylase activity, interaction with p53 pathways and inhibition of proteolytic processes that facilitate invasion. Aberrant epigenetic silencing, promoter methylation and loss of transcriptional regulation by p53 or PTEN are common mechanisms driving maspin downregulation in cancer. Clinically, maspin has been explored as a prognostic marker in breast, prostate, colorectal, lung and gastric cancers, with particular interest in its potential to predict response to chemotherapy and guide personalised therapies. Recent translational studies have also assessed maspin concentrations in biological fluids as non-invasive diagnostic indicators and evaluated gene therapy approaches to restore its expression. The global significance of maspin research lies in its dual role as a biomarker and as a candidate for targeted intervention, emphasising the need for standardised assays to quantify its expression and localisation.

Research from Nature Portfolio

In triple-negative breast cancer, recent work has revealed that patients exhibit higher cytoplasmic maspin expression compared to other molecular subtypes, with transcriptomic analyses confirming concordant mRNA upregulation. However, lower maspin levels within this subgroup correlate with reduced overall and metastasis-free survival, suggesting a context-dependent prognostic value that may inform clinical stratification. In a foundational genetic epidemiology study, haplotype analysis of SERPINB5 variants established associations between specific promoter and coding-region haplotypes and hepatocellular carcinoma risk. In silico functional prediction indicated that these variants modulate maspin expression and protein stability, providing a genetic risk model that may complement existing biomarkers for early detection and risk assessment in liver cancer populations.

Maspin Expression in Cancer Biology publication trend

The graph below shows the total number of articles in maspin expression in cancer biology across all publications each year (not limited to Nature Index journals).

Technical terms

Maspin: A non-inhibitory serine protease inhibitor (SERPINB5) acting as a tumour suppressor through regulation of apoptosis, adhesion and epigenetic enzymes.

Serine protease inhibitor (serpin): A family of proteins that typically inhibit serine proteases, although maspin lacks classical inhibitory activity.

Subcellular localisation: The distribution of a protein within cellular compartments (e.g. nucleus versus cytoplasm) influencing its functional role.

Epithelial-mesenchymal transition (EMT): A phenotypic switch enabling epithelial cells to acquire mesenchymal traits, promoting invasion and metastasis.

Prognostic marker: A biological characteristic that correlates with disease outcome, such as survival or response to therapy.

Haplotype: A group of genetic variants that tend to be inherited together, used to assess disease susceptibility.

Histone deacetylase 1 (HDAC1): An epigenetic enzyme that removes acetyl groups from histones, influencing gene expression and chromatin structure.

References

1. Opposing Functions of Maspin Are Regulated by Its Subcellular Localization in Lung Squamous Cell Carcinoma Cells. Cancers (2024).
2. Prognostic value of Maspin protein level in patients with triple negative breast cancer. Scientific Reports (2024).
3. Minimally Invasive and Fast Diagnosis of Gastric Cancer Based on Maspin Levels in Different Biological Samples. Diagnostics (2023).
4. Integrating the tumor-suppressive activity of Maspin with p53 in retuning the epithelial homeostasis: A working hypothesis and applicable prospects. Frontiers in Oncology (2022).
5. Serpin peptidase inhibitor (SERPINB5) haplotypes are associated with susceptibility to hepatocellular carcinoma. Scientific Reports (2016).